Tag: Immune checkpoint inhibitor
We read with interest the study published by Braaten and colleagues, analyzing the long-term outcomes of 60 patients developing persistent inflammatory arthritis (IA) after immune checkpoint inhibitors (ICIs) cessation.
27.01.2020
 
Immune checkpoint inhibitors (ICIs) are a new class of antineoplastic antibodies blocking inhibitory coreceptors on T cells. There are two classes of immune checkpoint receptor antibodies currently available, targeting either the cytotoxic T lymphocyte associated protein 4 (CTLA-4) or the programmed cell death 1 (PD-1) pathway.
22.01.2020
 
Immune checkpoint inhibitors block the checkpoint molecules. Different types of cancer immune checkpoint inhibitors have been approved recently: CTLA-4 monoclonal antibodies (as ipilimumab); anti-PD-1 monoclonal antibodies (as pembrolizumab and nivolumab); and anti-PD-L1 monoclonal antibodies (as atezolizumab, avelumab, and durmalumab).
16.07.2019
 
Immune checkpoint inhibitors block the checkpoint molecules. Different types of cancer immune checkpoint inhibitors have been approved recently: CTLA-4 monoclonal antibodies (as ipilimumab); anti-PD-1 monoclonal antibodies (as pembrolizumab and nivolumab); and anti-PD-L1 monoclonal antibodies (as atezolizumab, avelumab, and durmalumab)
09.07.2019
 
Autoimmune polyendocrine syndrome type 2 (APS-2) is a polygenic disease in which HLA alleles and non-HLA genes determine the targeting of specific tissues by autoreactive T cells, leading to organ-specific autoimmunity.
25.06.2019
 
By targeting inhibitory checkpoint molecules, with resultant reinvigoration of antitumor immunity, immune checkpoint inhibitors (ICIs) have opened a new chapter in cancer treatment [1].
27.03.2019
 
Myositis as an adverse event of immune checkpoint blockade for cancer therapy; Myositis as a complication of immune checkpoint blockade
01.07.2018